Integrating Biologics is Fastest Growing Segment Fueling the Growth of Osteoporosis Treatment Market11/27/2023 The global Osteoporosis Treatment Market is estimated to be valued at US$ 14.54 Bn in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview: Osteoporosis is a bone disease characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures. Biologics such as monoclonal antibodies are emerging as the fastest growing segment to treat severe osteoporosis as they can inhibit bone resorption and increase bone formation. Market key trends: The growing geriatric population is one of the key trends fueling the growth of the osteoporosis treatment market. As per the United Nations, the number of people aged 65 years and above is projected to reach 1.5 billion in 2050 from 703 million in 2019. Older people are at a higher risk of developing osteoporosis and bone fractures. Thus, rising life expectancy and aging baby boomer generation will propel the demand for osteoporosis medications over the forecast period. Segment Analysis The osteoporosis treatment market is dominated by the drug therapy segment. This segment accounts for over 70% of the total market share owing to the increasing adoption of branded as well as generic drug formulations for osteoporosis treatment. The drug therapy segment is further divided into several sub-segments such as parathyroid hormone therapy, selective estrogen receptor modulators (SERMs), bisphosphonates, calcitonin, and others. Among these, bisphosphonates dominate the market due to their proven efficacy and high prescription rate. Key Takeaways The Global Osteoporosis Treatment Market Size is expected to witness high growth, exhibiting CAGR of 3.8% over the forecast period, due to increasing incidence of osteoporosis cases globally. Regional analysis North America is currently the largest as well as the fastest growing regional market for osteoporosis treatment. This is majorly attributed to the rising prevalence of osteoporosis and growing geriatric population in the region. Asia Pacific market is expected to exhibit the highest growth rate over the forecast period owing to increasing awareness regarding osteoporosis treatment and improvement in healthcare facilities in emerging economies of the region. Key players Key players operating in the osteoporosis treatment market are Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy€TMs Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc. Read more: https://www.ukwebwire.com/osteoporosis-treatment-market-size-analysis/
0 Comments
|
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |